Hospital do Câncer de Londrina

What Hospital do Câncer de Londrina does

Hospital do Câncer de Londrina (HCL), legally registered as Instituto de Câncer de Londrina (CNPJ 78.633.088/0001-76), is a philanthropic nonprofit oncology hospital founded in 1965 and headquartered at Rua Lucilla Ballalai, 212, in Londrina, Paraná, Brazil. The institution provides a comprehensive suite of cancer services organized around two core specialties — Clinical Oncology and Surgical Oncology — supported by chemotherapy, radiotherapy, surgery, hospitalization (including a recognized pediatric ICU), diagnostic imaging and laboratory services, palliative care, and blood and bone marrow donation coordination. Digital patient services include telemedicine consultations via the Tuotempo platform and exam-result access via Pixeon, while medical education is delivered through accredited residency programs in surgical oncology and clinical oncology alongside clinical and academic research output.

HCL serves as a regional referral center, handling approximately 1,600 daily patient attendances drawn from 166 municipalities across Paraná as well as patients from other Brazilian states and other countries. Its self-described positioning places it as the second-ranked oncology hospital in Paraná and tenth in Brazil, with additional recognition for the best pediatric ICU in the state. The organization employs 501–1,000 staff across clinical, administrative, and educational functions.

The revenue model is a hybrid of SUS (Sistema Único de Saúde) reimbursements for publicly referred patients, convênio health-insurance reimbursements for privately covered patients, and a substantial philanthropic stream. Donations flow through multiple channels including Cofre Solidário, utility-bill and carnê donation campaigns, the Empresas Amigas corporate partnership program, and tax-deductible mechanisms under the PRONON (Programa Nacional de Apoio à Atenção Oncológica) and FIA/PR (State Fund for Childhood and Adolescence) programs. Recent infrastructure investments — a new building (2011–2013), a 3rd-floor expansion (2018), Pediatric Chemotherapy area (2018), Surgical Center, Emergency Room, and cafeteria — alongside the R$10M HCL Cancer Datachild technology modernization partnership with FIA/PR (2022) and an active PRONON-backed radiotherapy upgrade indicate ongoing capacity buildout and capital reinvestment, though no revenue trend data is publicly disclosed.

Name

Hospital do Câncer de Londrina

Legal name

Instituto de Câncer de Londrina

Website

https://hcl.org.br

Company type

Private

Founded year

1965

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Hospital do Câncer de Londrina (HCL) is a philanthropic nonprofit oncology hospital in Londrina, Paraná, Brazil, providing clinical oncology, surgical oncology, chemotherapy, radiotherapy, surgery, and palliative care to patients from 166 municipalities. Founded in 1965, it funds operations through SUS, convênios, and donations.

Ownership category

akta.pro rank

Product category

Oncology Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (6223), Other Ambulatory Health Care Services (6219), Ambulatory Health Care Services (621)

SIC

Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro industry

PRIMARYHLAFAHAC

Oncology & Cancer Specialty Hospitals

Healthcare & Life Sciences/Healthcare Providers & Systems/Specialty Hospitals & Inpatient Specialty Care

SECONDARYHLAFABAI

Ambulatory Oncology Centers (Outpatient Chemo/Radiation)

Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers

SECONDARYHLAKAFAB

Medical Oncology

Healthcare & Life Sciences/Specialist Medical Practice/Hematology & Oncology

SECONDARYHLAKAFAG

Surgical Oncology

Healthcare & Life Sciences/Specialist Medical Practice/Hematology & Oncology

Keywords

• Oncology hospital services
• Cancer treatment center
• Chemotherapy services
• Radiotherapy treatment
• Surgical oncology

Headquarters

HQ city

Londrina

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. SUS (Sistema Único de Saúde) reimbursements: Government-funded healthcare services through Brazil's public healthcare system
2. Health insurance reimbursements: Services covered by private health insurance plans through convênios
3. Donations and charitable contributions: Individual and corporate donations through various campaigns including Cofre Solidário, carnê donations, utility bill donations, PRONON, and FIA tax-deductible donations

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Hospital do Câncer de Londrina is a philanthropic cancer hospital providing comprehensive oncology care including clinical oncology, surgical oncology, chemotherapy, radiotherapy, hospitalization (with pediatric ICU), diagnostic imaging, laboratory examinations, and palliative care. The hospital also coordinates blood and bone marrow donation services, runs medical residency programs in oncology, and serves approximately 1,600 patients daily referred primarily through Brazil's public healthcare system (SUS) and private insurance networks.

Product overview

Hospital do Câncer de Londrina (HCL) is a filantropic cancer treatment hospital offering a comprehensive range of oncology services as a unified hospital institution. The core offerings include Clinical Oncology and Surgical Oncology (treated as distinct departments), supported by chemotherapy, radiotherapy, surgery, and hospitalization services. Diagnostic capabilities include laboratory and imaging exams. The hospital also provides palliative care and blood/bone marrow donation coordination. Digital patient services include telemedicine via Tuotempo and exam results via Pixeon portal. Medical education is delivered through residency programs in oncology surgery and clinical oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Oncology (Oncologia Clínica) Medical consultations and treatment planning for cancer patients using chemotherapy and other pharmacological interventions, delivered as a core oncology department at the hospital.
• Surgical Oncology (Oncologia Cirúrgica) Cancer treatment through surgical procedures performed by specialized oncological surgeons at the hospital.
• Chemotherapy (Quimioterapia) Administration of chemotherapy drugs for cancer treatment, including pediatric chemotherapy services.
• Radiotherapy (Radioterapia)

Segments3 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Empresas Amigas do HCL (Friendly Companies)minorOthersCorporate partnership program where companies support the hospital through donations and charitable contributions. Companies receive recognition and participate in solidarity campaigns.

Scale indicators4 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Hospital Erasto Gaertner: Philanthropic oncology hospital in Curitiba, Paraná, offering clinical and surgical oncology, radiotherapy, and pediatric care. Most direct geographic peer to HCL within Paraná state, competing for regional referrals and SUS patients in southern Brazil.
• AC Camargo Hospital: Major São Paulo-based oncology specialty hospital offering comprehensive clinical, surgical, and radiation oncology plus residency programs. Closest direct peer to HCL in service line breadth and academic orientation, though larger and based in Brazil's largest metro.

Broad incumbents

• Hospital Sírio-Libanês: Premier São Paulo-based private hospital with strong oncology service line including chemotherapy, radiotherapy, and surgical oncology. Competes with HCL for high-acuity private insurance and convênio patients willing to travel for tertiary cancer care.
• Hospital Israelita Albert Einstein: São Paulo-based high-end hospital offering comprehensive oncology care and active in cancer research and teaching. Comparable broad incumbent competing for premium-paying patients and complex oncology cases that might otherwise flow to HCL.
• Hospital de Amor de Barretos: Brazil's largest philanthropic cancer hospital network, headquartered in Barretos, São Paulo. Directly comparable to HCL as a nonprofit oncology specialty hospital, but operates at national scale with multiple campuses and is the dominant oncology referral center in Brazil.
• Instituto Nacional de Câncer (INCA): Brazil's federal cancer institute and leading public oncology reference center in Rio de Janeiro. Comparable to HCL in providing comprehensive cancer care including surgery, radiotherapy, and chemotherapy, but operates at national referral scale as the public-sector anchor for oncology in Brazil.

Regional players

• Hospital de Clínicas da UFPR: Public university hospital in Curitiba affiliated with the Federal University of Paraná, offering oncology services including chemotherapy and radiotherapy with academic residency programs. Comparable as Paraná-based oncology teaching hospital competing for SUS referrals and specialist training.
• Hospital de Câncer de Muriaé: Regional philanthropic cancer hospital in Minas Gerais offering oncology surgery, chemotherapy, and radiotherapy. Direct structural peer to HCL as a regional SUS-affiliated philanthropic oncology center, though operating in a different state and slightly smaller scale.
• Hospital Haroldo Juacaba: Philanthropic oncology hospital in Fortaleza, Ceará, providing comprehensive cancer treatment. Direct structural peer to HCL as a SUS-affiliated regional philanthropic cancer center, though operating in Brazil's Northeast region.

Emerging players

• Hospital Pequeno Príncipe: Philanthropic pediatric hospital in Curitiba with a growing pediatric oncology service line. Comparable to HCL's pediatric oncology niche, including the recognized pediatric ICU capability, and competes for the same donor base and SUS pediatric oncology referrals in Paraná.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/HospitalDoCancerDeLondrina
• LinkedInlinkedin.com/company/hclondrina

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hospital do Câncer de Londrina